Sleep Disordered Breathing Is Highly Prevalent in Patients with Lung Cancer: Results of the Sleep Apnea in Lung Cancer Study

Fecha de publicación: 01/01/2019

Autores de IIS La Fe

Miguel Ángel Martínez García

Autor

Participantes ajenos a IIS La Fe

Cabezas, E
Perez-Warnisher, MT
Troncoso, MF
Gomez, T
Melchor, R
Pinillos, EJ
El Hachem, A
Gotera, C
Rodriguez, P
Fernandez, IM
Gonzalez-Mangado, N
Peces-Barba, G
Seijo, LM

Grupos

Neumología

Leader

Miguel Ángel Martínez García

Abstract

Background: Obstructive sleep apnea (OSA) has been linked to tumorigenesis and tumor progression. Objectives: The Sleep Apnea in Lung Cancer (SAIL) study (NCT02764866) was designed to determine the prevalence of OSA in patients with lung cancer. Methods: Cross-sectional study including consecutive patients with newly diagnosed lung cancer. All patients were offered home sleep apnea testing (HSAT) and administered a sleep-specific questionnaire prior to initiating oncologic treatment. Sleep study-related variables, symptoms, and epidemiologic data as well as cancer related variables were recorded. Results: Eighty-three patients were enrolled in the SAIL study. Sixty-six completed HSAT. The mean age was 68 +/- 11 years and 58% were male with a mean body mass index of 28.1 +/- 5.4. Forty-seven percent were current smokers, 42% former smokers, and 11% never smokers with a median tobacco consumption of 51 pack-years. Fifty percent had COPD with a mean FEV1 of 83 +/- 22.6% of predicted and a mean DLCO of 85.5 +/- 20.1%. Adenocarcinoma was the most common histologic type (46.7%), followed by squamous cell (16.7%) and small cell (16.7%). Most patients were diagnosed at an advanced stage (65% in stages III-IV). The vast majority (80%) had OSA (apnea-hypopnea index [AHI] > 5), and 50% had moderate to severe OSA (AHI > 15) with a mean Epworth Sleepiness Score of 7.43 +/- 3.85. Significant nocturnal hypoxemia was common (Median T90: 10.9% interquartile range 2.4-42.2). Conclusions: Sleep apnea and nocturnal hypoxemia are highly prevalent in patients with lung cancer. (C) 2018 S. Karger AG, Basel